Overview
Therapeutic monoclonal antibodies are one of the fastest growing classes of drugs, and interleukins and their signal pathways are a preeminent target for treatments due to the vast number of problems their improper regulation present. Surface plasmon resonance (SPR) is a powerful tool that is well-suited for analyzing the binding interactions associated with signaling proteins, their receptors and related effectors.
In this application note, we demonstrate Alto’s applicability to the development of monoclonal antibody therapeutics, with a focus on interleukin and interleukin-related therapies